A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer
Purpose: Mutation of the Kirsten ras sarcoma viral oncogene homolog (KRAS) and loss of p53 function are commonly seen in patients with non–small cell lung cancer (NSCLC). Combining therapeutics targeting these tumor-defensive pathways with cisplatin in a single-nanoparticle platform are rarely devel...
Main Authors: | Gu, Li, Deng, Zhou J., Roy, Sweta, Hammond, Paula T |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Chemical Engineering |
Format: | Article |
Language: | English |
Published: |
American Association for Cancer Research (AACR)
2021
|
Online Access: | https://hdl.handle.net/1721.1/130536 |
Similar Items
-
Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer
by: Mensah, Lawrence B., et al.
Published: (2022) -
Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer
by: Mensah, Lawrence B, et al.
Published: (2021) -
Osteotropic Therapy via Targeted Layer-by-Layer Nanoparticles
by: Morton, Stephen Winford, et al.
Published: (2014) -
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
by: Rita Chiari, et al.
Published: (2023-11-01) -
Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
by: Wenbo Qi, et al.
Published: (2023-01-01)